ATE531372T1 - Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren - Google Patents
Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitorenInfo
- Publication number
- ATE531372T1 ATE531372T1 AT09730921T AT09730921T ATE531372T1 AT E531372 T1 ATE531372 T1 AT E531372T1 AT 09730921 T AT09730921 T AT 09730921T AT 09730921 T AT09730921 T AT 09730921T AT E531372 T1 ATE531372 T1 AT E531372T1
- Authority
- AT
- Austria
- Prior art keywords
- spirocyclic
- gem
- disubstituted
- aminopyridines
- pyrimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12327908P | 2008-04-07 | 2008-04-07 | |
| PCT/US2009/039678 WO2009126584A1 (en) | 2008-04-07 | 2009-04-06 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE531372T1 true ATE531372T1 (de) | 2011-11-15 |
Family
ID=40905030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09730921T ATE531372T1 (de) | 2008-04-07 | 2009-04-06 | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8389533B2 (de) |
| EP (1) | EP2278973B1 (de) |
| JP (1) | JP5530422B2 (de) |
| AT (1) | ATE531372T1 (de) |
| AU (1) | AU2009233951B2 (de) |
| CA (1) | CA2719538C (de) |
| MX (1) | MX2010010975A (de) |
| WO (1) | WO2009126584A1 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| MX2013010871A (es) * | 2011-03-23 | 2014-01-31 | Amgen Inc | Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3. |
| EP2760845B1 (de) | 2011-09-27 | 2016-11-16 | Amgen Inc. | Heterocyclische verbindungen als mdm2-hemmer zur behandlung von krebs |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US20150353542A1 (en) | 2013-01-14 | 2015-12-10 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| JP6417338B2 (ja) | 2013-02-19 | 2018-11-07 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| EA036942B1 (ru) | 2013-11-11 | 2021-01-18 | Эмджен Инк. | Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| JP6751203B2 (ja) | 2016-06-07 | 2020-09-02 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｓｈｐ２阻害剤として有用な新規複素環式誘導体 |
| TWI749126B (zh) | 2016-12-16 | 2021-12-11 | 大陸商基石藥業（蘇州）有限公司 | Cdk4/6抑制劑 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| ES2985118T3 (es) | 2017-09-08 | 2024-11-04 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| EP3788038B1 (de) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras-g12c-inhibitoren und verfahren zu deren verwendung |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| EP3807276B1 (de) | 2018-06-12 | 2025-12-10 | Amgen Inc. | Einen piperazinring umfassende kras g12c-inhibitoren und ihre verwendung zur krebsbehandlung |
| WO2020063760A1 (en) | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| TWI840489B (zh) | 2019-01-11 | 2024-05-01 | 日商鹽野義製藥股份有限公司 | 酮衍生物 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| EP3738593A1 (de) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosierung von kras-inhibitor zur behandlung von krebserkrankungen |
| KR20250159270A (ko) | 2019-05-21 | 2025-11-10 | 암젠 인크 | 고체 상태 형태 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
| CN110787163B (zh) * | 2019-12-05 | 2020-06-02 | 河北医科大学第二医院 | 一种用于神经保护和促进神经再生的药物组合物及其制剂 |
| US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN113880809B (zh) | 2020-07-03 | 2022-10-18 | 盛世泰科生物医药技术(苏州)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| KR20220021651A (ko) | 2020-08-14 | 2022-02-22 | 롬엔드하스전자재료코리아유한회사 | 유기 전계 발광 화합물, 복수 종의 호스트 재료 및 이를 포함하는 유기 전계 발광 소자 |
| EP4153552A2 (de) | 2020-09-01 | 2023-03-29 | Firmenich SA | Verfahren und zwischenprodukte zur herstellung von 3-(cyclohex-1-en-1-yl)-propanalderivaten |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1168290A (en) | 1964-08-27 | 1969-10-22 | Allen & Hanburys Ltd | Novel Heterocyclic Compounds |
| IT1153216B (it) | 1981-10-16 | 1987-01-14 | Schering Ag | Procedimento per la preparazione di composti cianoeterociclici |
| US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| BR0015718A (pt) * | 1999-11-22 | 2002-07-23 | Warner Lambert Co | Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina |
| BR0109056A (pt) * | 2000-03-06 | 2003-06-03 | Warner Lambert Co | Inibidores da cinase de tirosina de 5-alquilpirido[2,3-d]pirimidinas |
| HK1054039B (zh) | 2000-03-15 | 2010-04-16 | 萨诺费－阿文蒂斯德国有限公司 | 取代的β-咔啉 |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| ATE276257T1 (de) | 2000-06-30 | 2004-10-15 | Banyu Pharma Co Ltd | Pyrazinonderivate |
| ES2324763T3 (es) * | 2000-10-31 | 2009-08-14 | Aventis Pharmaceuticals Inc. | Derivados acilo y sulfonilo de 2-(trans-1,4-diaminociclohexil)-purinas 6,9-disustituidas y su uso como agentes antiproliferativos. |
| WO2002076396A2 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| ES2251677T3 (es) | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| WO2003062246A1 (en) | 2002-01-22 | 2003-07-31 | Warner-Lambert Company Llc | 2-thia-1,6,8-triaza-naphtalene-2,2-dioxides as cdk inhibitors |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| DE602004021558D1 (de) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| AU2004240772B2 (en) | 2003-05-22 | 2011-04-28 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors |
| GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| AU2004285052A1 (en) | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (AZA) quinoline derivatives as capsaicin receptor agonists |
| GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| BRPI0507852A (pt) | 2004-02-18 | 2007-07-10 | Warner Lambert Co | 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| GB0403606D0 (en) | 2004-02-18 | 2004-03-24 | Novartis Ag | Organic compounds |
| ATE407119T1 (de) * | 2004-02-24 | 2008-09-15 | Glaxo Group Ltd | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors |
| WO2005094830A1 (en) | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| WO2005110410A2 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| EP1761281A1 (de) | 2004-06-04 | 2007-03-14 | Pfizer Products Incorporated | Verfahren zur behandlung von abnormalem zellwachstum |
| CA2569404A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| EP1786817A1 (de) | 2004-08-26 | 2007-05-23 | Boehringer Ingelheim International GmbH | Pteridinone als plk (polo like kinase) inhibitoren |
| US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| CN101035526A (zh) | 2004-10-13 | 2007-09-12 | 默克公司 | 用于治疗高眼压的眼用组合物 |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| AU2006205851A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| AU2006207325B2 (en) | 2005-01-21 | 2012-08-16 | Astex Therapeutics Limited | Pharmaceutical compounds |
| GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP1896472A1 (de) | 2005-06-09 | 2008-03-12 | Boehringer Ingelheim International GmbH | Alpha-carboline als cdk-1 inhibitoren |
| CA2619362A1 (en) | 2005-08-19 | 2007-03-01 | Schering Corporation | Fused tricyclic mglur1 antagonists as therapeutic agents |
| AU2006283592A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| CA2627623C (en) | 2005-10-06 | 2014-04-22 | Schering Corporation | Methods for inhibiting protein kinases |
| US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| MX2008013110A (es) | 2006-04-12 | 2009-03-06 | Vertex Pharma | 4-5-dihidro-[1,2,4]triazolo[4,3-f]pteridinas como inhibidores de la proteina-cinasa plk1 para el tratamiento de trastornos proliferativos. |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| EP2026805A1 (de) | 2006-05-08 | 2009-02-25 | Astex Therapeutics Limited | Pharmazeutische kombinationen aus diazolderivaten zur krebsbehandlung |
| US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| US20070270362A1 (en) | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
| JO3235B1 (ar) * | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| ES2365258T3 (es) | 2006-06-26 | 2011-09-27 | Ucb Pharma S.A. | Derivados de tiazol condensados como inhibidores de quinasa. |
| RU2009108006A (ru) | 2006-09-08 | 2010-10-20 | Пфайзер Продактс Инк. (Us) | Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов |
| AU2007301126A1 (en) * | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| EP2109450A2 (de) | 2006-12-14 | 2009-10-21 | Panacea Pharmaceuticals, Inc. | Verfahren zur neuroprotektion durch cyclin-abhängige kinasehemmung |
| MX2009006863A (es) | 2006-12-20 | 2009-08-28 | Schering Corp | Inhibidores novedosos de c-jun-n-terminal cinasas. |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| WO2009014642A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
| US7960400B2 (en) | 2007-08-27 | 2011-06-14 | Duquesne University Of The Holy Ghost | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
| US7982035B2 (en) | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| PE20091195A1 (es) | 2007-11-07 | 2009-08-06 | Schering Corp | Nuevos moduladores de los puntos de control del ciclo celular y su uso en combinacion con inhibidores de quinasa de punto de control |
| BRPI0821209A2 (pt) | 2007-12-19 | 2019-09-24 | Amgen Inc | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
| JP2011509078A (ja) | 2007-12-28 | 2011-03-24 | イプソゲン | 乳癌発現プロファイリング |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
-
2009
- 2009-04-06 AT AT09730921T patent/ATE531372T1/de active
- 2009-04-06 US US12/936,725 patent/US8389533B2/en active Active
- 2009-04-06 CA CA2719538A patent/CA2719538C/en not_active Expired - Fee Related
- 2009-04-06 AU AU2009233951A patent/AU2009233951B2/en not_active Ceased
- 2009-04-06 MX MX2010010975A patent/MX2010010975A/es active IP Right Grant
- 2009-04-06 WO PCT/US2009/039678 patent/WO2009126584A1/en not_active Ceased
- 2009-04-06 EP EP09730921A patent/EP2278973B1/de active Active
- 2009-04-06 JP JP2011504114A patent/JP5530422B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2719538C (en) | 2014-03-18 |
| EP2278973B1 (de) | 2011-11-02 |
| US8389533B2 (en) | 2013-03-05 |
| CA2719538A1 (en) | 2009-10-15 |
| EP2278973A1 (de) | 2011-02-02 |
| US20110097305A1 (en) | 2011-04-28 |
| JP2011516558A (ja) | 2011-05-26 |
| WO2009126584A1 (en) | 2009-10-15 |
| JP5530422B2 (ja) | 2014-06-25 |
| MX2010010975A (es) | 2010-11-01 |
| AU2009233951A1 (en) | 2009-10-15 |
| AU2009233951B2 (en) | 2014-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE531372T1 (de) | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren | |
| TN2010000236A1 (en) | Fused pyridine pyrimidine and triazine compounds as cell cycle inhibitors | |
| ATE457311T1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine | |
| TR201810944T4 (tr) | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. | |
| AU2011278832A8 (en) | Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors | |
| NZ715838A (en) | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof | |
| CL2012000591A1 (es) | Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados. | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| MY192467A (en) | 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides | |
| MX2022008904A (es) | Sintesis de gamma-carbolinas fusionadas con heterociclo substituido. | |
| PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
| MX2009010728A (es) | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. | |
| CL2012002250A1 (es) | Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer. | |
| AU2012356374A8 (en) | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors | |
| HRP20080377B1 (hr) | ANTAGONISTI AKTIVIN-ActRIIa I PRIMJENE ZA STIMULACIJU RASTA KOSTI | |
| MY149960A (en) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases | |
| WO2010129053A8 (en) | Egfr inhibitors and methods of treating disorders | |
| DE602007008545D1 (de) | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors | |
| JO3283B1 (ar) | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) | |
| EP2614051A4 (de) | P53-mdm2-antagonisten | |
| TN2011000404A1 (en) | Fused pyrimidines | |
| EA201491376A1 (ru) | Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы | |
| MX382891B (es) | Composiciones y métodos para tratar trastornos de proliferación. | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| MA32544B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |